The buyer clubs and executive access framework we install for every client for healthcare and life sciences in the Middle East
A repeatable, seven-part framework for running buyer clubs and executive access as a system — the same one we use inside every Growth Broker engagement. Written for commercial leaders at healthtech, medtech, and life-sciences companies in the Middle East.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in the Middle East. In this market, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing, so the way you install buyer clubs and executive access has to be shaped to that reality from day one.
We have installed buyer clubs and executive access inside more than fifty companies. This is the framework we reach for every time. Buyer clubs and executive access is curated rooms where the buyer walks in already predisposed to hear you, and the framework exists to keep that definition honest under real conditions.
Part one, diagnosis. Before you touch the model, name the constraint: finance, demand, access, or conversion. Buyer clubs and executive access applied to the wrong constraint is theatre.
Part two, target. Narrow to one industry, one role, one trigger. Every extra dimension halves conversion.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in the Middle East it is compounded by the fact that senior-relationship access, not product is what actually gates growth. Buyer clubs and executive access is only useful here when it is pointed at both constraints at once.
Part three, offer. What is the buyer's next step, and what makes it obvious? The offer, not the copy, is what carries.
Part four, engine. Tools, sequences, data. Buy the minimum you can operate; every extra tool is a future dependency.
Part five, operating rhythm. Monday plan, Friday review, weekly cycle length from first touch to closed-won. Nothing about the model is left to memory.
Parts six and seven, learning and allocation. What did we learn last week; where does next week's dollar go. Once those two loops are live, buyer clubs and executive access compounds and the framework stops being visible.
Concretely for healthcare and life sciences in the Middle East: the healthcare teams that install this get past procurement instead of dying in it, and one sovereign or family-office win in the Middle East justifies a full year of program spend. That is the reason it is worth installing buyer clubs and executive access deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Buyer Access · healthcare · Middle East — answered
- Does buyer clubs and executive access work for healthcare and life sciences in the Middle East?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing. The healthcare teams that install this get past procurement instead of dying in it.
- Do I need all seven parts to see results?
- Diagnosis, target, and operating rhythm are the non-negotiables. The others can lag by weeks, not quarters.
- How long does the framework take to install?
- Six to twelve weeks depending on the state of the data and the size of the team.
- Can I adapt the framework to my stack?
- The framework is stack-agnostic. Tooling is part four and is the most swappable piece.
- What is the biggest risk to the framework?
- Confusing sponsorship with membership — usually because a stakeholder shortcuts diagnosis to get to spend.
- What is the Middle East-specific pitfall when running buyer clubs and executive access for healthcare?
- Importing a playbook that was built for another market. In the Middle East, Middle Eastern buyers reward in-person credibility, sovereign fit, and patient sequencing — the install has to reflect that.
Growth Broker editorial
Filed under buyer access · healthcare · middle east